What is ART-TG ?

The Technological Research Accelerator in Genomic Therapy (ART-TG) is a public R&D innovation center established by Inserm, the french national biomedical institution, to promote excellence in gene therapy research.

 

Our mission:

Advancing novel cell and gene therapy concepts towards clinical trials by bridging a gap between researchers/clinicians and industries, .

What do we provide ?

Dedicated scientific and pharmaceutical expertise for ex vivo ATMPs

Pre-GMP environment

 

Grant-funded scientific collaborations

 

Service contracts

 

Domains of interest:

Two fields in which gene therapy has high innovation potential:

     immunotherapy (e.g. cancer, infectious diseases)

     genetic disorders (especially sickle cell disease)

Our location: 

Within the Genopole campus, south of Paris, France.​

Part of the "integrator" MAGENTA:

In 2020, the french government created the concept of "integrator" to recognize laboratories capable of addressing the challenges of industrial production of biomedicines.

The MAGENTA "integrator" was co-founded by ART-TG to foster innovation in cell and gene therapy by functioning at the public/private interface.

 

Contact us:
ART-TG seeks partners looking to innovate in the field of genomic therapy.
Inserm Transfert accompanies the partnerships of ART-TG.  

art-tg@inserm.fr

logo_inserm.jpg
logo_genopole.png
logo_magenta.png
logo_insermtransfert.png

Team

IMGP1207.JPG

Anne Galy, PharmD, PhD
Director 
(ORCID)
CV online

 

mario_amendola.png

Mario Amendola, PhD

Expert Genome Editing
(ORCID)

Our projects are funded by

logo_inserm_edited.jpg
Inserm_logo_anrs.jpg
Agence_Nationale_de_la_Recherche_edited.
imi_logo.png
téléchargement.png
vri.jpg
logo_ridf.jpg
logo_dim_tg.jpg
logo_dim1_health.png
logo_genopole.png
inca-345x190_7.jpg
logobpi.png